Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the feasibility of randomizing individuals to low
molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The
investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo
randomization, and complete the allocated treatment group.